Rubicon Research Peer Comparison
NSE: RUBICON | BSE: 544578
₹1,819.60
₹15.20
(0.84%)
As on 31-Aug-2026 15:31IST
Market cap
₹30,155 Cr
Revenue (TTM)
₹1,936 Cr
P/E Ratio
104.6
P/B Ratio
22.5
Div. Yield
0.1 %
Edit
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
30,155 | 30,809 | 28,424 | 26,403 | 20,584 |
Revenue (₹ Cr) |
1,936 | 3,564 | 9,205 | 1,462 | 5,632 |
Net Profit (₹ Cr) |
288.22 | 414.00 | -371.81 | 387.35 | 662.35 |
Net Margin (%) |
14.79 | 11.23 | -3.93 | 26.01 | 11.75 |
RoE (%) |
29.77 | 8.38 | -3.85 | 25.18 | 14.34 |
Price to Earnings |
104.63 | 75.33 | -- | 68.36 | 31.08 |
Price-To-Book |
22.46 | 6.12 | 3.55 | 15.27 | 4.20 |
Income Statement (₹ Cr)
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Operating Revenue
|
1,753.96 | 3,373.00 | 8,869.08 | 1,006.88 | 5,365.64 |
|
Total Income
|
1,762.66 | 3,510.00 | 9,111.51 | 1,023.80 | 5,385.97 |
|
Total Expenditure
|
1,354.69 | 2,747.00 | 7,976.59 | 774.80 | 4,180.50 |
|
EBITDA
|
399.26 | 626.00 | 892.49 | 232.07 | 1,185.14 |
|
Depreciation
|
45.26 | 227.00 | 831.24 | 26.62 | 296.14 |
|
EBIT
|
354.00 | 399.00 | 61.25 | 205.45 | 889.00 |
|
Interest
|
42.17 | 213.00 | 340.80 | 6.22 | 114.35 |
|
Other Income
|
8.70 | 137.00 | 242.43 | 16.93 | 20.33 |
|
Exceptional Items
|
-- | -85.00 | -196.14 | -- | -10.00 |
|
Profit before Tax
|
320.53 | 238.00 | -176.06 | 216.16 | 784.98 |
|
Provision for Tax
|
73.80 | 39.00 | 149.88 | 55.75 | 189.96 |
|
Profit after Tax
|
246.74 | 199.00 | -325.94 | 160.42 | 595.02 |
Liabilities (₹ Cr)
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
1,288.82 | 4,940.00 | 8,162.62 | 1,309.63 | 5,085.00 |
|
Minority Interest
|
0.00 | 341.00 | -- | 10.45 | -- |
|
Non-Current Liabilities
|
189.02 | 1,235.00 | 4,529.41 | 26.93 | 479.08 |
|
Current Liabilities
|
835.87 | 1,622.00 | 4,874.74 | 202.25 | 2,092.03 |
|
Total Liabilities
|
2,326.71 | 8,578.00 | 17,723.32 | 1,549.26 | 7,682.91 |
Assets (₹ Cr)
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
631.90 | 5,441.00 | 10,258.66 | 757.63 | 3,888.46 |
|
Current Assets
|
1,681.81 | 2,606.00 | 7,308.11 | 791.64 | 3,767.65 |
|
Total Assets
|
2,326.71 | 8,578.00 | 17,723.32 | 1,549.26 | 7,682.91 |
|
Total Debt*
|
259.37 | 2,125.00 | 5,495.48 | 8.18 | 1,338.13 |
|
Net Current Assets
|
845.94 | 984.00 | 2,433.37 | 589.39 | 1,675.62 |
|
Contingent Liabilities
|
19.09 | 768.26 | 95.72 | 15.38 | 0.93 |
Cashflow (₹ Cr)
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
205.05 | 390.00 | 1,652.60 | 118.34 | 793.25 |
|
Cash Flow from Investing Activities
|
-409.72 | -241.00 | -826.03 | -223.94 | -773.21 |
|
Cash from Financing Activities
|
283.07 | -54.00 | -38.98 | 261.12 | 379.29 |
|
Net Cash Inflow / Outflow
|
78.39 | 95.00 | 787.59 | 155.52 | 399.33 |
Ratios
Profitability Ratios
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
ROCE (%)
|
29.22 | 6.79 | 1.24 | 20.14 | 15.74 |
|
ROE (%)
|
27.84 | 4.29 | -4.04 | 16.19 | 14.13 |
|
ROA (%)
|
13.11 | 2.53 | -1.98 | 12.13 | 8.60 |
|
EBIT Margin (%)
|
23.26 | 22.62 | 12.80 | 24.73 | 22.47 |
|
Net Margin (%)
|
14.00 | 5.67 | -3.58 | 15.67 | 11.05 |
|
Cash Profit Margin (%)
|
7.71 | 10.98 | 4.80 | 18.58 | 8.89 |
Growth Ratios
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
36.57 | 11.99 | -3.08 | 40.34 | 19.73 |
|
EBIT Growth (%)
|
52.29 | 67.69 | -28.15 | 83.12 | 25.81 |
|
Net Profit Growth (%)
|
83.64 | 449.12 | -457.66 | 229.35 | 18.64 |
|
EPS Growth (%)
|
71.44 | 553.20 | -456.91 | 67.16 | 16.13 |
|
Book Value Growth (%)
|
144.31 | 13.47 | 0.33 | 94.96 | 27.49 |
Valuation Ratios
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Price / Earnings
|
51.69 | 89.54 | 0.00 | 62.97 | 25.87 |
|
Price / Book Value
|
10.14 | 3.87 | 2.24 | 15.26 | 3.26 |
|
Dividend Yield (%)
|
0.19 | 0.00 | 0.00 | 0.06 | 0.28 |
|
EV/EBITDA
|
31.05 | 27.45 | 19.72 | 79.31 | 13.09 |
|
Market Cap (₹ Cr)
|
12,753.19 | 19,071.62 | 18,108.89 | 19,988.69 | 15,391.88 |
Solvency Ratios
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.21 | 0.43 | 0.68 | 0.01 | 0.28 |
|
Short term debt to equity ratio
|
0.05 | 0.09 | 0.09 | 0.01 | 0.20 |
|
Current Ratio
|
2.01 | 1.61 | 1.50 | 3.91 | 1.80 |
|
Quick Ratio
|
1.14 | 1.06 | 0.87 | 3.02 | 1.00 |
|
Interest Coverage
|
8.60 | 2.12 | 0.48 | 35.76 | 7.86 |
Operating Efficiency Ratios
| Rubicon Research | Wockhardt | Piramal Pharma | Acutaas Chemicals | Granules India | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
29.00 | 17.43 | 24.33 | 28.85 | 16.95 |
|
Asset Turnover
|
2.01 | 0.49 | 0.64 | 0.76 | 1.45 |
|
Receivable days
|
40.13 | 58.75 | 78.20 | 90.06 | 33.72 |
|
Inventory Days
|
60.29 | 75.82 | 93.30 | 61.02 | 54.92 |
|
Payable days
|
232.47 | 186.21 | 226.14 | 96.06 | 136.11 |
|
Cash Conversion Cycle
|
-132.04 | -51.64 | -54.64 | 55.02 | -47.47 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
